C. Molta

Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation

Mechanism and medical implications of mammalian autophagy

Efficacy of systemic therapies for moderate‐to‐severe psoriasis: a systematic review and meta‐analysis of long‐term treatment

Anti-phosphatidylethanolamine (aPE) Antibodies: a Survey

Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics

Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence

Psoriasis

Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis

Chronic inflammatory diseases: Do immunological patterns drive the choice of biotechnology drugs? A critical review

Clinical practice guideline for an integrated approach to comorbidity in patients with psoriasis

The Antiphospholipid Syndrome

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010

A family study of anticardiolipin antibodies and associated clinical conditions

A multicenter, randomized, open-label pilot trial assessing the efficacy and safety of etanercept 50 mg twice weekly followed by etanercept 25 mg twice weekly, the combination of etanercept 25 mg twice weekly and acitretin, and acitretin alone in patients with moderate to severe psoriasis

Tumour necrosis factor-α inhibitor therapy in chronic physical illness: A systematic review and meta-analysis of the effect on depression and anxiety

Autophagy: controlling cell fate in rheumatic diseases

Macrophage Cytokines: Involvement in Immunity and Infectious Diseases

Moyamoya Disease and Moyamoya Syndrome

Etiology of stroke in children

The role of inflammation in depression: from evolutionary imperative to modern treatment target

Drug therapies for peripheral joint disease in psoriatic arthritis: a systematic review.

The family history of patients with primary or secondary antiphospholipid syndrome (APS)

Psoriasis Pathogenesis and Treatment

Guidelines for the Primary Prevention of Stroke

CAR T cell immunotherapy for human cancer

Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial

Self‐reported health outcomes in patients with psoriasis and psoriatic arthritis randomized to two etanercept regimens

Efficacy and safety of etanercept in children and adolescents aged≥8 years with severe plaque psoriasis

The risk of psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in European dermatology clinics

Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care

Efficacy and safety of continuous versus paused etanercept treatment in patients with moderate-to-severe psoriasis over 54 weeks: the CRYSTEL study

Childhood-Onset Systemic Lupus Erythematosus: Antiphospholipid Antibodies in 37 Patients and Their First-Degree Relatives

The efficacy and safety of etanercept when used with as-needed adjunctive topical therapy in a randomised, double-blind study in subjects with moderate-to-severe psoriasis (the PRISTINE trial)